Tenax Therapeutics (TENX) Research & Development (2010 - 2026)
Tenax Therapeutics (TENX) posted quarterly Research & Development of $12.8 million for Q2 2026, up 109.93% year-over-year from $6.1 million in Q2 2025, and up 11.36% on a QoQ basis from $11.5 million in Q1 2026.
Tenax Therapeutics (TENX) Research & Development (2010 - 2026) Analysis & Trends
Tenax Therapeutics has reported Research & Development for 16 years, with the latest figure at $12.8 million in Q2 2026.
- Research & Development for Q2 2026 came in at $12.8 million, up 109.93% year-over-year; the trailing twelve-month figure through Jun 2026 was $45.3 million (up 131.97% YoY), and the FY2025 annual result was $32.7 million, up 157.08% from the prior year.
- Research & Development grew to $12.8 million in Q2 2026, from $11.5 million in the prior quarter.
- Over five years, Research & Development peaked at $12.8 million in Q2 2026 and troughed at $197903.0 in Q2 2023.
- A 5-year average of $4.4 million and a median of $2.5 million in 2024 frame the typical range for Research & Development.
- The widest annual swing landed in 2022, when Research & Development sank 94.74%; it then jumped 1075.83% in 2024.
- A 5-year view of Research & Development shows it stood at $1.1 million in 2022, then soared by 49.76% to $1.7 million in 2023, then surged by 170.31% to $4.6 million in 2024, then soared by 129.43% to $10.5 million in 2025, then climbed by 21.92% to $12.8 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $12.8 million in Q2 2026, $11.5 million in Q1 2026, and $10.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Tenax Therapeutics | 80.73 Mn | 80.73 Mn | - | 12.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.85 Mn |
| Mar 31, 2026 | 11.54 Mn |
| Dec 31, 2025 | 10.54 Mn |
| Sep 30, 2025 | 10.33 Mn |
| Jun 30, 2025 | 6.12 Mn |
| Mar 31, 2025 | 5.68 Mn |
| Dec 31, 2024 | 4.59 Mn |
| Sep 30, 2024 | 3.11 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | 2.68 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 197,903.00 |
| Mar 31, 2023 | 265,735.00 |
| Dec 31, 2022 | 1.13 Mn |
| Sep 30, 2022 | 1.54 Mn |
| Jun 30, 2022 | 1.52 Mn |
| Mar 31, 2022 | 1.18 Mn |
| Dec 31, 2021 | 915,600.00 |
| Sep 30, 2021 | 1.16 Mn |